ABIONYX: 2026 Half-Year Results and Future Strategies

ABIONYX Pharma has published its financial results for the first half of 2026. The biopharmaceutical company reports cash of €26.9 million as of June 30, 2026, before receipt of tax credits and aid from the France 2030 plan. Half-year revenue amounted to €1.9 million, generated exclusively by the subsidiary IRIS Pharma.

Research and development expenses were reduced to €570,000, and administrative costs remained stable at €1,807,000. Despite these optimizations, ABIONYX recorded a net loss of €4.814 million as of June 30, 2026. IRIS Pharma's revenue is projected to remain stable in 2026.

The company is pursuing its strategy focused on developing therapies for sepsis and LCAT deficiency, with production compliant with GMP standards, supported by the France 2030 plan. It anticipates financial support of 8.7 million euros from this program.